Menu
Search Close

Technology

CIMT Winter School January 12-16, 2019

Healthy individuals have a repertoire of CD4 cells that recognize and respond to citrullinated peptides - a possible new target for cancer immunotherapy?

Ruhul Hasan Choudhury, Ian Daniels, Vicky Brentville, Katherine Cook, Peter Symonds, Poonam Bilimoria, Suha Atabani, Rachael Metheringham, Lindy Durrant 


CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference : Translating Science into Survival 2018

CRI 2018 : Post translationally modified homocitrulline induced by MDSCs can be an effective anti-tumour target for CD4 T cells

K. Cook, W. Xue, P. Symonds, M. Gijon, P. Vaghela, R. Choudhury, S. Shah, S. Atabani, R. Metheringham, V. Brentville, L. Durrant 

CRI 2018 : Pre-existing citrulline specific CD4 T cells can be efficiently harnessed for tumour therapy

V. Brentville, P. Symonds, K. Cook, I. Daniels, S. Atabani, R. Choudhury, P. Vaghela, R. Metheringham, M. Gijon, W. Xue, L. Durrant

CRI 2018 : Targeting gastrointestinal tumors with constant region-engineered anti-glycan antibodies

M. Vankemmelbeke, T. Kirk, C. Papagregoriou, S. Aziz, J.X. Chua, R.S. McIntosh, L.G. Durrant


International Cancer Immunotherapy Conference 2017

CRI 2017 Peptide/TLR agonist conjugates poster

V. Brentville, K. Cook, P. Symonds, G.G. Zom, W. Xue, R. Metheringham, W-J. Krebber, C.J.M. Melief and L.G. Durrant

CRI 2017 Modi-1, a novel cancer vaccine

L. G. Durrant, R. Metheringham, I. Daniels, K. Cook, P. Symonds, T. Pitt, W. Xue, M. Gijon and V. Brentville


Progress in Vaccination against Cancer 2016

PIVAC 2016 SCIB1 Clinical Trial Poster

L.G. Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, R. Metheringham, V.Brentville, S. Adams, L. Machado, I. Daniels, D. Hannaman and P.M. Patel 

PIVAC 2016 Adjuvants for Moditope Poster

Katherine Cook, Peter Symonds, Victoria Brentville, Rachael Metheringham,  Wei Xue and Lindy Durrant

PIVAC 2016 Citrullinated Alpha Enolase Poster

K. Cook, I. Daniels, V. Brentville, R. Metheringham, W. Xue, P. Symonds, T. Pitt, M.Gijon and L. Durrant

PIVAC 2016 Protein Arginine Deiminase Enzymes Poster

R. Metheringham, M. Gijon, I. Daniels, K. Cook, P. Symonds, T. Pitt, W. Xue, V. Brentville and L. Durrant


Progress in Vaccination against Cancer 2015

PIVAC 2015 SCIB2 Poster

Wei Xue, Rachael Metheringham, Victoria Brentville, Katherine Cook, Peter Symonds, Ian Daniel and Lindy Durrant

PIVAC 2015 Moditope poster 2

V. Brentville, W. Xue, P. Symonds, K. Cook, B. Gunn, R. Metheringham and L.G. Durrant

PIVAC 2015 SCIB1 resected disease

L.G. Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, R. Metheringham, V. Brentville, L. Machado, I. Daniels, D. Hannaman and P.M. Patel

PIVAC 2015 SCIB1 plus checkpoint inhibition

Wei Xue, Victoria Brentville, Rachael Metheringham, Katherine Cook, Peter, Symonds, Ian Daniels and Lindy Durrant


American Society of Clinical Oncology 2015

ASCO June 2015 Poster

P.M. Patel, C. Ottensmeier, C. Mulatero, P.Lorigan, R. Plummer, M.  Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels, D. Hannaman and L.G. Durrant


American Association for Cancer Research 2015

AACR Moditope Poster April 2015

Victoria A.  Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Wei Xue and Lindy G. Durrant


American Society of Clinical Oncology 2014

ASCO Poster June 2014

P.M. Patel, L.G. Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, M. Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels and D. Hannaman


Webcasts, Interviews and Media Coverage

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

Thu, 31 Jan 2019 08:41:00

Award shortlist 'a significant scientific endorsement' of Scancell's technology

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive London's Andrew Scott the company's received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for a major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

Wed, 23 Jan 2019 12:25:00